Activities of (Poly)phenolic Antioxidants and Other Natural Autophagy Modulators in the Treatment of Sanfilippo Disease: Remarkable Efficacy of Resveratrol in Cellular and Animal Models

Author:

Rintz Estera,Podlacha Magdalena,Cyske Zuzanna,Pierzynowska Karolina,Węgrzyn Grzegorz,Gaffke LidiaORCID

Abstract

AbstractSanfilippo disease, caused by mutations in the genes encoding heparan sulfate (HS) (a glycosaminoglycan; GAG) degradation enzymes, is a mucopolysaccharidosis (MPS), which is also known as MPS type III, and is characterized by subtypes A, B, C, and D, depending on identity of the dysfunctional enzyme. The lack of activity or low residual activity of an HS-degrading enzyme leads to excess HS in the cells, impairing the functions of different types of cells, including neurons. The disease usually leads to serious psychomotor dysfunction and death before adulthood. In this work, we show that the use of molecules known as dietary (poly)phenolic antioxidants and other natural compounds known as autophagy activators (genistein, capsaicin, curcumin, resveratrol, trehalose, and calcitriol) leads to accelerated degradation of accumulated HS in the fibroblasts of all subtypes of MPS III. Both the cytotoxicity tests we performed and the available literature data indicated that the use of selected autophagy inducers was safe. Since it showed the highest effectivity in cellular models, resveratrol efficacy was tested in experiments with a mouse model of MPS IIIB. Urinary GAG levels were normalized in MPS IIIB mice treated with 50 mg/kg/day resveratrol for 12 weeks or longer. Behavioral tests indicated complete correction of hyperactivity and anxiety in these animals. Biochemical analyses indicated that administration of resveratrol caused autophagy stimulation through an mTOR-independent pathway in the brains and livers of the MPS IIIB mice. These results indicate the potential use of resveratrol (and possibly other autophagy stimulators) in the treatment of Sanfilippo disease.

Funder

Narodowe Centrum Nauki

Fundacja Sanfilippo Poland

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Reference79 articles.

1. Węgrzyn G, Pierzynowska K, Jakobkiewicz-Banecka J, et al. Mucopolysaccharidosis type III: clinical features, biochemistry, diagnosis, genetics, and treatment. In: Mucopolysaccharidoses Update; Tomatsu S, Lavery C, Giugliani R, Hermatz P, Scarpa M, Węgrzyn G, Orii T, Eds. Nova Publishers: Hauppauge, NY, USA, 2018; Volume 1, pp. 211–233.

2. Pierzynowska K, Rintz E, Gaffke L, et al. Mucopolysaccharidosis type III (Sanfilippo disease) subtypes A, B, C, D: molecular mechanism and therapeutic effect. In: Tomatsu S, Lavery C, Giugliani R, Hermatz P, Scarpa M, Węgrzyn G, Orii T, editors., et al., Mucopolysaccharidoses Update. Hauppauge, NY, USA: Nova Publishers; 2018. p. 51–101.

3. Heon-Roberts R, Nguyen ALA, Pshezhetsky AV. Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease. J Clin Med. 2020;9:344. https://doi.org/10.3390/jcm9020344.

4. Benetó N, Vilageliu L, Grinberg D, Canals I. Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches. Int J Mol Sci. 2020;21:7819. https://doi.org/10.3390/ijms21217819.

5. Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013;102:462–70.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3